English

First Quarter Report Q1-2024

Report this content

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2024. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. ​

First quarter financial results 2024 (1 January - 31 March): ​

  • Net revenue was KDKK 0​
  • Operating result was KDKK -4.079 ​
  • Net result was KDKK -2.711​
  • Cash at bank end of the period was KDKK 15.041​
  • Earnings per share* was KDKK -0,16​
  • Solidity** was 95% ​

The Company has advanced well with its planned activities​

  • US planning & preparation for CT001 launch​
  • CT001 device verification completed​
  • Study 0202 initiation visits and supply of IMP medicine ​
  • Submission of abstract for unified PK-PD model in children ​

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 March 2024 amounted to 17.425.094 shares, the average number of shares during the first quarter was 16.602.837 ​
**Solidity: Total equity divided by total capital and liability ​

Comment from CEO, Jes Trygved: 
Our focus has also very much been on the planning and preparation for the US launch of CT001 where we expect to have first packs shipped to selected US hospitals under the Early Access Program in just a few months. Thanks to teams for its efficiency, hard work and commitment for making this possible. We are also pleased to soon initiate the Paediatric Safety Study 0202, which is the final clinical trial before we can prepare for regulatory submission for CT001, and we have submitted an abstract on the paediatric population data, a PK-PD model, which will be presented end of June at a conference in Europe. ​

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.

Subscribe

Documents & Links